Order results by:
| Issue | Title | |
| Vol 10, No 4 (2017) | INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW | Abstract similar documents |
| D. G. Tolkacheva, A. V. Torgov, A. S. Margazova | ||
| "... the reference group of drugs. However, today’s control of biosimilar pricing in Europe is just building up ..." | ||
| Vol 10, No 4 (2017) | INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW | Abstract similar documents |
| D. G. Tolkacheva, A. V. Torgov, A. S. Margazova | ||
| "... the reference group of drugs. However, today’s control of biosimilar pricing in Europe is just building up ..." | ||
| Vol 11, No 1 (2018) | Options to optimize the access to biosimilars: analysis and solutions | Abstract similar documents |
| O. V. Kirsanova, V. V. Omelyanovsky | ||
| "... products – biosimilars – in the Russian Federation and elsewhere (USA, EU) are addressed. We propose ..." | ||
| Vol 11, No 3 (2018) | What is the role of antineoplastic drug safety in reimbursement decision making? | Abstract similar documents |
| A. S. Kolbin, A. A. Kurylev | ||
| "... Rationale. From 2014 to 2017, the portion of antineoplastic drugs dossiers submitted ..." | ||
| Vol 11, No 1 (2018) | Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... disappears, and the CA drugs have a lower CER instead. For the «number of hospitalization-free days per year ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... was increased to 24 months, this economic advantage of AA diminished, and the kA drugs had a lower CeR instead ..." | ||
| Vol 10, No 4 (2017) | THE INTERNATIONAL PRACTICE OF DRUG SUPPLY IN THE OUTPATIENT SEGMENT | Abstract similar documents |
| D. V. Lukyantseva, L. S. Mel’nikova, A. P. Tatarinov | ||
| "... The paper examines the international experience of drug supply and the risks faced by countries ..." | ||
| Vol 11, No 1 (2018) | Modeling microbial drug-resistance: from mathematics to pharmacoeconomics | Abstract similar documents |
| Yu. M. Gomon, M. A. Arepyeva, Yu. E. Balykina, A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, S. V. Sidorenko | ||
| "... optimal algorithm for using antimicrobial agents (AMA) that would minimize the evolving drug-resistance ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov | ||
| "... are registered in second-line, however only dasatinib is included in the government drug reimbursement program ..." | ||
| Vol 11, No 3 (2018) | The concept of multi-criteria analysis of decision-making in the current system of health technology assessment in Russia | Abstract similar documents |
| V. V. Omelyanovsky, V. K. Fedyaeva, N. Z. Musina | ||
| Vol 10, No 4 (2017) | IMPROVEMENT OF PRICE REGULATION FOR INNOVATIVE MEDICINES COVERED BY THE NATIONAL BUDGET | Abstract similar documents |
| V. A. Lemeshko, N. Z. Musina, V. K. Fedyaeva | ||
| "... The current approaches to the drug pricing commonly used worldwide allow for incorporating ..." | ||
| Vol 11, No 3 (2018) | Use of medications in children hospitalized with community-acquired pneumonia | Abstract similar documents |
| D. D. Siukaeva, I. A. Narkevich, V. N. Timchenko, O. D. Nemyatyh, N. A. Maslova | ||
| "... respiratory tract prevailed (32.20%). As for the medications, the category J drugs “Antimicrobials of systemic ..." | ||
| Vol 11, No 2 (2018) | Regional adaptation of the federal model of reimbursement for medical assistance based on clinical statistical groups: hospitalization of patients in need of genetically enginered biological preparations | Abstract similar documents |
| M. V. Sura, T. N. Ignatova, N. S. Rudneva, Yu. N. Sukhanova, N. G. Ulyanova, A. S. Khudyaev, V. A. Shelyakin, D. V. Scherbakov | ||
| "... in the costs of different drug therapy regimens. ..." | ||
| Vol 11, No 3 (2018) | Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus | Abstract similar documents |
| A. G. Tolkushin, N. L. Pogudina | ||
| "... from analysis of published clinical and observational studies. The prices of the relevant drugs were ..." | ||
| Vol 11, No 3 (2018) | Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review | Abstract similar documents |
| D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin | ||
| "... . In the ocrelizumab group, the most common adverse events were caused by reactions to the drug infusion ..." | ||
| 1 - 15 of 15 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
